AAAAAA
Results:
1-16
|
Results: 16
Authors:
Klingemann, HG
Citation: Hg. Klingemann, Cellular therapy: Finishing the job, J HEMATH ST, 10(4), 2001, pp. 435-436
Authors:
English, D
Klingemann, HG
Citation: D. English et Hg. Klingemann, The foundations of cellular therapy: Barnes and Loutit, 1957, J HEMATH ST, 10(3), 2001, pp. 323-324
Authors:
Maki, G
Klingemann, HG
Martinson, JA
Tam, YK
Citation: G. Maki et al., Factors regulating the cytotoxic activity of the human natural killer cellline, NK-92, J HEMATH ST, 10(3), 2001, pp. 369-383
Authors:
Klingemann, HG
Citation: Hg. Klingemann, Cellular therapy of cancer with natural killer cells: Will it ever work?, J HEMATH ST, 10(1), 2001, pp. 23-26
Authors:
McCaul, KG
Nevill, TJ
Barnett, MJ
Toze, CL
Currie, CJ
Sutherland, HJ
Conneally, EA
Shepherd, JD
Nantel, SH
Hogge, DE
Klingemann, HG
Citation: Kg. Mccaul et al., Treatment of steroid-resistant acute graft-versus-host disease with rabbitantithymocyte globulin, J HEMATH ST, 9(3), 2000, pp. 367-374
Authors:
Klingemann, HG
Citation: Hg. Klingemann, Immunotherapy with dendritic cells: Coming of age?, J HEMATH ST, 9(2), 2000, pp. 127-128
Authors:
Klingemann, HG
Citation: Hg. Klingemann, Relevance and potential of natural killer cells in stem cell transplantation, BIOL BLOOD, 6(2), 2000, pp. 90-99
Authors:
Toze, CL
Shepherd, JD
Connors, JM
Voss, NJ
Gascoyne, RD
Hogge, DE
Klingemann, HG
Nantel, SH
Nevill, TJ
Phillips, GL
Reece, DE
Sutherland, HJ
Conneally, EA
Barnett, MJ
Citation: Cl. Toze et al., Allografting for indolent lymphoid neoplasms, ANN ONCOL, 11, 2000, pp. 59-61
Authors:
Reece, DE
Brockington, DA
Phillips, GL
Barnett, MJ
Klingemann, HG
Nantel, SH
Sutherland, HJ
Shepherd, JD
Citation: De. Reece et al., Prolonged survival after intensive therapy and purged ABMT in patients with multiple myeloma, BONE MAR TR, 26(6), 2000, pp. 621-626
Authors:
Toze, CL
Shepherd, JD
Connors, JM
Voss, NJ
Gascoyne, RD
Hogge, DE
Klingemann, HG
Nantel, SH
Nevill, TJ
Phillips, GL
Reece, DE
Sutherland, HJ
Barnett, MJ
Citation: Cl. Toze et al., Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia, BONE MAR TR, 25(6), 2000, pp. 605-612
Authors:
Klingemann, HG
Citation: Hg. Klingemann, Mechanical ventilation for bone marrow transplant patients: When does it become futile?, CRIT CARE M, 28(3), 2000, pp. 899-900
Authors:
Tam, YK
Miyagawa, B
Ho, VC
Klingemann, HG
Citation: Yk. Tam et al., Immunotherapy of malignant melanoma in a SCID mouse model using the highlycytotoxic natural killer cell line NK-92, J HEMATOTH, 8(3), 1999, pp. 281-290
Authors:
Hennemann, B
Tam, YK
Tonn, T
Klingemann, HG
Citation: B. Hennemann et al., Expression of SCM-1 alpha/lymphotactin and SCM-1 beta in natural killer cells is upregulated by IL-2 and IL-12, DNA CELL B, 18(7), 1999, pp. 565-571
Authors:
Tam, YK
Maki, G
Miyagawa, B
Hennemann, B
Tonn, T
Klingemann, HG
Citation: Yk. Tam et al., Characterization of genetically altered, interleukin 2-independent naturalkiller cell lines suitable for adoptive cellular immunotherapy, HUM GENE TH, 10(8), 1999, pp. 1359-1373
Authors:
Reece, DE
Nevill, TJ
Sayegh, A
Spinelli, JJ
Brockington, DA
Barnett, MJ
Klingemann, HG
Connors, JM
Nantel, SH
Shepherd, JD
Sutherland, HJ
Voss, NJS
Fairey, RN
O'Reilly, SE
Phillips, GL
Citation: De. Reece et al., Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease, BONE MAR TR, 23(11), 1999, pp. 1131-1138
Authors:
Micallef, INM
Chhanabhai, M
Gascoyne, RD
Shepherd, JD
Fung, HC
Nantel, SH
Toze, CL
Klingemann, HG
Sutherland, HJ
Hogge, DE
Nevill, TJ
Le, A
Barnett, MJ
Citation: Inm. Micallef et al., Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience, BONE MAR TR, 22(10), 1998, pp. 981-987
Risultati:
1-16
|